Skip to main content

Table 4 Student's t-test (paired) analyses for comparison of the scores obtained from the low-dose and high-dose 5-Loxin® groups at day 90

From: A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee

  n Baseline Day 90 95% CI (versus placebo) P
   Mean SD Mean SD   
Visual analogue scale score
   Placebo 23 56.88 12.04 41.76 15.98   <0.05
   100 mg 5-Loxin® 24 57.05 8.71 21.37 7.13 -27.67, -13.11 <0.0001
   250 mg 5-Loxin® 23 55.62 9.26 14.22 6.8 -34.94, -20.19 <0.0001
Lequesne's Functional Index
   Placebo 23 12.76 2.6 10.19 3.24   0.031
   100 mg 5-Loxin® 24 12.1 2.76 7.78 4.61 -4.74, -0.07 <0.0001
   250 mg 5-Loxin® 23 12.04 3.03 7 3.5 -5.19, -1.18 <0.0001
WOMAC pain subscale
   Placebo 23 38.04 2.03 31.74 2.58   0.1212
   100 mg 5-Loxin® 24 42.08 2.93 19.17 3.55 -21.33, to -3.83 <0.0001
   250 mg 5-Loxin® 23 37.17 2.88 15.22 2.50 -23.78 to -9.28 <0.0001
WOMAC stiffness subscale
   Placebo 23 33.15 2.73 24.45 2.37   0.2983
   100 mg 5-Loxin® 24 31.77 3.61 14.06 3.71 -38.87, -6.85 <0.0001
   250 mg 5-Loxin® 23 27.72 3.44 9.24 2.07 -43.35, -17.45 <0.0001
WOMAC function subscale
   Placebo 23 41.30 2.02 34.07 1.09   0.1048
   100 mg 5-Loxin® 24 41.48 2.31 24.32 4.28 -18.64, -0.82 <0.0001
   250 mg 5-Loxin® 23 38.56 2.32 17.267 1.98 -21.39, -12.23 <0.0001
MMP-3 (ng/ml)
   Placebo 15 902.1 275.6 928.5 216.02   0.4886
   100 mg 5-Loxin® 16 893.6 270.1 637.2 224.5   <0.0001
   250 mg 5-Loxin® 14 926.9 270.5 497.5 167.5   <0.0001
  1. CI, confidecne interval; MMP, matrix metalloproteinase; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.